Verici Dx Plc (GB:VRCI) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Verici Dx Plc, a developer of advanced clinical diagnostics for organ transplant, has announced a delay in revenue recognition for its TutiviaTM test to FY25 due to a postponed Medicare coverage determination. Despite the delay, the company maintains a strong cash position and expects year-end balances to meet market expectations, with continued collaborations and anticipated revenue acceleration once insurance coverage is established in 2025.
For further insights into GB:VRCI stock, check out TipRanks’ Stock Analysis page.
